This is a StreetInsider.com Premium Only Page

(VYNE) – StreetInsider.com Reports

Jan 10, 2024 08:03 AM VYNE Therapeutics (VYNE) Reports Positive Biomarker Data from Successful Phase 1b Trial of VYN201

Jan 3, 2024 08:03 AM VYNE Therapeutics (VYNE) Appoints Christine Borowski to its Board

Nov 13, 2023 04:39 PM VYNE Therapeutics (VYNE) Announces 39.27M Share Offering by Selling Stockholders

Oct 31, 2023 06:43 AM VYNE Therapeutics (VYNE) PT Lowered to $5.75 at H.C. Wainwright

Oct 30, 2023 07:20 AM VYNE Therapeutics (VYNE) Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023 07:05 AM VYNE Therapeutics (VYNE) Announces Private Placement of $88 Million

Oct 30, 2023 07:01 AM VYNE Therapeutics (VYNE) Reports Positive Data from Phase 1b Trial of VYN201

May 12, 2023 06:33 AM VYNE Therapeutics (VYNE) PT Raised to $9 at Cantor Fitzgerald

May 11, 2023 05:28 PM VYNE Therapeutics Inc. (VYNE) Misses Q1 EPS by 159c

May 1, 2023 08:03 AM VYNE Therapeutics (VYNE) Announces Selection of Development Candidate VYN202

Apr 19, 2023 08:08 AM VYNE Therapeutics (VYNE) Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Mar 30, 2023 07:45 AM VYNE Therapeutics (VYNE) Reports Positive First-In-Human Data from Phase 1a Ascending Dose Trial of VYN201

Mar 14, 2023 06:35 AM VYNE Therapeutics (VYNE) PT Raised to $28 at H.C. Wainwright

Feb 28, 2023 04:00 PM VYNE Therapeutics (VYNE) Regains Nasdaq Compliance

Feb 15, 2023 08:05 AM VYNE Therapeutics (VYNE) Announces Positive Results from Phase 1a Trial for VYN201

Feb 10, 2023 08:01 AM VYNE Therapeutics (VYNE) Announces 1:18 Reverse Stock Split

Jan 4, 2023 04:33 PM U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.40%

Dec 7, 2022 08:13 AM VYNE Therapeutics (VYNE) Announces First Patent Granted for Novel BET Inhibitor Platform

Nov 10, 2022 05:12 PM VYNE Therapeutics Inc. (VYNE) Tops Q3 EPS by 1c

Aug 10, 2022 08:33 AM VYNE Therapeutics (VYNE) Reports Phase 2 Study of VY2021-01 Did Not Meet Primary Endpoint

Jun 22, 2022 04:44 AM Stocks with Implied Volatility Movement

May 18, 2022 06:08 AM H.C. Wainwright Reiterates Buy Rating, $7 Price Target on VYNE Therapeutics (VYNE)

May 13, 2022 06:27 AM Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 Price Target, Expects "Upwards Earnings Estimate Revisions and Multiple Expansion"

Apr 7, 2022 09:08 AM Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 PT, Sees Latest FMX114 Data Underscoring "Positive Investment Thesis"

Apr 7, 2022 08:00 AM VYNE Therapeutics (VYNE) Reports Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

Mar 17, 2022 10:55 AM Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) Overwight, $10 PT, Sees Company's Bromodomain and Extra-Terminal Domain Inhibitors Programs are Underappreciated

Mar 7, 2022 07:36 AM Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight, Newest Data Supports Positive Thesis for Stock

Mar 7, 2022 07:03 AM VYNE Therapeutics (VYNE) Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo

Jan 19, 2022 08:00 AM VYNE Therapeutics (VYNE) Reports Phase 1b Data for FMX114 from Phase 1b/2a Trial

Jan 13, 2022 09:46 AM H.C. Wainwright Assumes VYNE Therapeutics (VYNE) at Buy

Jan 13, 2022 09:27 AM Pre-Open Stock Movers 01/13: (BTCS) (ADGI) (PBYI) Higher; (DNLI) (SPCE) (ESTC) Lower (more...)

Jan 13, 2022 08:12 AM VYNE Therapeutics (VYNE) MST Sale is Good news, Underscores Company's Ability to Execute - Cantor Fitzgerald

Jan 13, 2022 07:02 AM VYNE Therapeutics (VYNE) Sells Topical Minocycline Assets to Journey Medical (DERM)

Dec 28, 2021 05:55 AM VYNE Therapeutics (VYNE) and Ardelyx (ARDX) Top Cantor Fitzgerald's Most Shorted Biotech List

Dec 6, 2021 09:25 AM Pre-Open Stock Movers 12/06: (TACO) (ACET) (VYNE) Higher; (LCID) (RIOT) (MARA) Lower (more...)

Dec 6, 2021 06:10 AM H.C. Wainwright Assumes VYNE Therapeutics (VYNE) at Buy

Nov 10, 2021 01:31 PM Cantor Fitzgerald Reiterates Overweight Rating on VYNE Therapeutics (VYNE)

Aug 13, 2021 09:28 AM VYNE Therapeutics (VYNE) PT Lowered to $3 at Piper Sandler

Aug 12, 2021 12:19 PM VYNE Therapeutics (VYNE) PT Lowered to $4 at Cowen

Mar 1, 2021 08:10 AM VYNE Therapeutics (VYNE) Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis

Feb 11, 2021 08:07 AM VYNE Therapeutics (VYNE) Announces 1-for-4 Reverse Stock Split

Feb 1, 2021 08:08 AM VYNE Therapeutics (VYNE) Announces FDA Approval of AMZEEQ Label Update

Jan 26, 2021 08:00 AM VYNE Therapeutics (VYNE) Announces $50 Million Registered Direct Offering of Common Stock

Jan 21, 2021 08:10 AM VYNE Therapeutics (VYNE) Announces Contract Execution for AMZEEQ and ZILXI with Major Pharmacy Benefit Management Company

Dec 17, 2020 08:03 AM VYNE Therapeutics (VYNE) Announces Successful End-of-Phase 2 Meeting with FDA for FCD105 in Acne

Dec 15, 2020 08:01 AM VYNE Therapeutics (VYNE) Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (minocycline) topical foam, 4%

Dec 7, 2020 04:36 PM VYNE Therapeutics (VYNE) Director Buys 50K Shares

Dec 1, 2020 08:06 AM VYNE Therapeutics (VYNE) Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic Dermatology

Oct 29, 2020 07:15 AM Companies with NDRs 10/29

Oct 28, 2020 06:53 AM Companies with NDRs 10/28